The Stochastic Oscillator for CRL moved out of overbought territory on October 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 67 similar instances where the indicator exited the overbought zone. In 52 of the 67 cases the stock moved lower. This puts the odds of a downward move at 78%.
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRL as a result. In 65 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for CRL turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 34 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
CRL broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Following a +2.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRL advanced for three days, in 199 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 146 of 228 cases where CRL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. CRL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.044) is normal, around the industry mean (63.909). P/E Ratio (-62.374) is within average values for comparable stocks, (1.606). Projected Growth (PEG Ratio) (0.122) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.340) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
LUCD saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 30, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 40 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 87%.
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LUCD as a result. In 81 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LUCD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for LUCD entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where LUCD advanced for three days, in 197 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
LUCD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. LUCD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.595) is normal, around the industry mean (2.908). P/E Ratio (-0.920) is within average values for comparable stocks, (2.616). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (21.645) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LUCD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
CRL | ||
|---|---|---|
OUTLOOK RATING 1..100 | 10 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 93 | |
PRICE GROWTH RATING 1..100 | 8 | |
P/E GROWTH RATING 1..100 | 81 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CRL | LUCD | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 89% |
| Stochastic ODDS (%) | 1 day ago 78% | 1 day ago 87% |
| Momentum ODDS (%) | 1 day ago 76% | 1 day ago 84% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 87% |
| TrendWeek ODDS (%) | 1 day ago 73% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 68% | 1 day ago 83% |
| Advances ODDS (%) | 6 days ago 70% | 13 days ago 80% |
| Declines ODDS (%) | 1 day ago 70% | 1 day ago 82% |
| BollingerBands ODDS (%) | 1 day ago 70% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 64% | 1 day ago 81% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRL’s FA Score shows that 2 FA rating(s) are green while LUCD’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRL’s TA Score shows that 2 TA indicator(s) are bullish while LUCD’s TA Score has 4 bullish TA indicator(s).
CRL (@Medical Specialties) experienced а -0.61% price change this week, while LUCD (@Medical/Nursing Services) price change was -36.83% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.29%. For the same industry, the average monthly price growth was -4.26%, and the average quarterly price growth was +44.85%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -3.67%. For the same industry, the average monthly price growth was -9.97%, and the average quarterly price growth was -11.02%.
CRL is expected to report earnings on Nov 04, 2026.
LUCD is expected to report earnings on Nov 16, 2026.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-3.67% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GCC | 26.82 | 0.07 | +0.26% |
| WisdomTree Enhanced Commodity Strategy Fund (GCC) | |||
| QQUP | 60.10 | N/A | N/A |
| ProShares Ultra Top QQQ | |||
| ABXB | 18.68 | N/A | N/A |
| Abacus Flexible Bond Leaders ETF (ABXB) | |||
| PAB | 40.55 | -0.14 | -0.33% |
| PGIM Active Aggregate Bond ETF (PAB) | |||
| EQTY | 29.32 | -0.11 | -0.37% |
| Kovitz Core Equity ETF (EQTY) | |||
A.I.dvisor tells us that LUCD and FEMY have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LUCD and FEMY's prices will move in lockstep.
| Ticker / NAME | Correlation To LUCD | 1D Price Change % | ||
|---|---|---|---|---|
| LUCD | 100% | -21.05% | ||
| FEMY - LUCD | 30% Poorly correlated | -1.21% | ||
| BFLY - LUCD | 28% Poorly correlated | +3.03% | ||
| CNMD - LUCD | 27% Poorly correlated | -1.43% | ||
| CRL - LUCD | 27% Poorly correlated | -0.04% | ||
| ELMD - LUCD | 26% Poorly correlated | -0.07% | ||
More | ||||